GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
In connection with Vitrolife’s (STO:VITR) distribution of the shares in Xvivo Perfusion AB, the Swedish Tax Agency has decided that 77% of the acquisition cost should be allotted to Vitrolife AB and 23% to Xvivo Perfusion AB.
